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Summary: Four immunochemical methods for digoxin assay were used to analyse control samples, 33 amniotic
fluid samples, 57 samples from digitalis-treated, non-pregnant women, 90 pregnancy serum samples, and 72
samples of fetal or neonatal serum with or without digoxin therapy. One hundred and five samples were also
submitted to ultrafiltration before analysis.
Three methods (RIA, TDX, AMERLITE) showed practically the same precision, while the precision of the
DELFIA was markedly inferior. In the analysis of serum samples from digoxin-treated, non-pregnant women,
RIA and TDX gave practically the same values, whereas AMERLITE and DELFIA gave significantly higher
values.
Pregnancy serum and fetal serum contain "digoxin-like immunoreactive factors", and the qualitative and
quantitative effects of these interfering factors are different for each of the four methods. The greatest
sensitivity to "digoxin-like immunoreactive factors" is shown by TDX and DELFIA, while the lowest
interference by "digoxin-like immunoreactive factors" is found in the analysis of ultrafiltered samples, using
the TDX method.
The composition of the "digoxin-like immunoreactive factors" in pregnancy serum and in fetal serum is
altered by digoxin therapy, and these changes have different effects on the various analytical methods. The
concentration of "digoxin-like immunoreactive factors" in the serum of fetuses receiving digoxin is markedly
lower than that of healthy fetuses.
For the reliable monitoring of digoxin therapy in the maternal and fetal circulation, the blood samples must
be submitted to ültrafiltration before analysis.
Introduction ^ compensation (1-4). For this purpose, digitalis
Fetal tachyarrhythmia — supraventriculär tachycar- agents are preferred, but in most cases they must be
dia and atrial flutter - in utero can lead to fetal combined with other antiarrthythmic drugs (4). When
congestive heart failure with the signs of non-immune hydrops is absent or not very pronounced, this con-
hydrops, and to death of the fetus. The reliable pre- ventional transplacental therapy is almost always suc-
natal diagnosis of this condition is nowdays possible cessful, provided the dose is sufficiently high. In the
by sonographic and echocardiographic investigation presence of a backward failure with pronounced hy-
of the fetus. Transplacental treatment of the fetus by drops, however, it is frequently unsuccessful (5).
the administration of antiarrhythmic agents to the
mother ean lead to cardioversion of the tachyarrhyth- Possible reasons for failure of the therapy are an
mia to a sinus rhythm with consecutive cardiac re- altered responsiveness of the affected fetal heart and/
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or a decreased placental transfer of the antiarrhythmic
agents, due to disturbed placental diffusion during
the period of fetal congestive heart failure (5—7).
Decreased placental transfer of digoxin has been con-
firmed by determination of digoxin in the maternal
and umbilical blood of hydropic newborn infants (7).
Further, by repeated sampling of fetal blood (punc-
ture of the umbiljcal vein is performed with sono-
graphic monitoring), and simultaneous determination
of digoxin in maternal and fetal blood, it has been
shown that the placental transfer of digoxin is mark-
edly decreased during tachyarrhythmia with hydrops,
but that it becomes normal after cardioversion and
cardiac recompensation (8).
In cases of tachycardia with hydrops refractory to
antiarrhythmic treatment, in addition to performing
transplacental therapy, it is therefore expedient to also
inject antiarrhythmic agents into the fetus to achieve
therapeutic concentrations in the fetal compartments.
For this purpose, injections are made into the umbil-
ical vein under sonographic guidance. Simultaneously,
the fetal blood concentration of the antiarrhythmic
agents is measured, on the one hand to monitor the
therapy, and on the other hand to obtain urgently
needed pharmacokinetic data (8).
Transplacental treatment with digitalis agents is also
recommended and carried out for other fetal condi-
tions involving congestive heart failure with hydrops,
such äs structural malformations, coccygeal teratoma,
twin transfusion syndrome and parasitic twin (9).
Placental transfer is also assumed to be deficient in
these cases, a fact which we have already confirmed
by fetal blood analysis (unpublished results). In all
these cases, it is necessary to test the efficiency of
intrauterine therapy by determining drug concentra-
tions in the maternal and fetal circulation, especially
since the high doses of digitalis can also eventually
endanger the health of the mother.
The clinical chemical laboratory therefore requires a
method for digoxin determination in single, emer-
gency samples, which produces results äs quickly äs
possible, and which is not subject to interference by,
e. g. "digoxin-like immunoreactive factors (DLIF)".
"Digoxin-like immunoreactive factors" have been
found in the blood of patients with liver and kidney
illnesses, in pregnant women and newborn infants,
and in amniotic fluid, the reported concentrations
showing a marked dependency on the determination
method (10-14).
In the present work, the influence of "digoxin-like
immunoreactive factors" on three non-radioactive im-
munochemical methods and a radioimmunoassay for
digoxin were investigated, and a procedure for the
elimination of "digoxin-like immunoreactive factors"
was tested.
Materials and Methods , ,
Samples
"Digoxin-like immunoreactive factors" concentrations were de-
termined in semm samples from 50 healthy, pregnant women
between the 16th and 40th week of pregnancy, in 20 umbilical
sera from healthy, mature, newborn infants, and in 32 fetal
blood samples from fetuses between the 18th and 34th week of
pregnancy. Fetal blood samples were obtained by puncture of
the fetal umbilical vein with sonographic monitoring (15), and
33 amniotic fluid samples were obtained between the 24th and
35th week of pregnancy by transabdominal puncture. All serum
samples were also submitted to Ultrafiltration.
For the comparison of methods, 57 sera from non-pregnant
women under digoxin therapy were selected, and 35 of these
were also submitted to ultrafiltration.
Additionally, 40 serum samples from pregnant women treated
for foetal tachyarrhythmia with digoxin were analysed. All
samples were also subjected to ultrafiltration.
Finally, 30 blood samples were investigated from fetuses be-
tween the 25th and 36th week of pregnancy, who had been
treated either by administration of digitalis preparations to the
mother, or by direct injection of the drugs into the umbilical
vein. In all samples, the digoxin concentration was deterrnined
with TDX before and after ultrafiltration. Owing to the limited
sample volumes, it was possible to anaiyse only 20 samples
with RIA, DELFIA and AMERLITE.
All sera were analysed within 6 houf s of sampling, or stored at
-20°C until analysis.
Controls
For the determination of precision, 4 control samples were
used, supplied by the "Deutsche Gesellschaft für Klinische
Chemie".
Methods
The following analytical methods were used:
1. Fluorescence-polarization-immunoassay (TDX); TDX Di-
goxin II (Abbott Laboratories, Diagnostics Division, Chicago,
USA).
2. Time-resolved fluoroimmunoassay (DELFIA); DELFIA Di-
goxin kit (Wallac Oy, Turku, Finland).
3. Enhanced luminescence immunoassay (AMERLITE);'
AMERLITE^Digoxin-Assay (Amersham International plc,
Little Chalfont, England).
4. Radio-immunoassay (RIA); Coat-A-Count Digoxin
(Diagnostic Product Corporation, Los Angeles, USA).
All determinations were performed according tp the instructions
of the manufacturers.
Ultraf i l t rat ion
Based on the work of Graves (16) and Christenson (17), 500
serum were pipetted into the sample reservoir of a filter (Cen-
trifee Micropartition System* YMT-membrane, exclusion limit
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30 000 Dalton, Amicon Division, Danvers, USA), and allowed
to equilibrate at least l h at 4 °C. It was then centrifuged for
45 min at -4-4 °C and 1500g, using a 45° fixed angle rotor. An
aliquot (200 μΐ) of the filtrate was diluted with 200 μΐ sulpho-
salicylic acid (140 mrool/1 in aqueous methanol, volume fraction
0.5) and analysed by fluorescence-polarization-immunoassay
(TDX).
Contrary to the reports of Christenson (17), the protein-free
ultraflltrate could not be analysed without this dilution step.
Statistics
The minimum detection limit of the assays was calculated
according to Borth (18). The within-run Standard deviation was
calculated from sample duplicates with concentrations below
0.8 nmol/1 (19).
For the comparison of methods, the regression equations were
calculated according to the procedure of Passing & Bablok (20).
Mass concentrations can be calculated from the following re-
lationship: l μg/l = 1.28 nmol/1.
Results
The data for precision in series and from day to day
for the investigated methods are summarized in
table l. The minimum detection limit was determined
s 0.06 nmol/1 (TDX), 0.11 nmol/1 (DELFIA), 0.07
nmol/1 (AMERLITE), and 0.09 nmol/1 (RIA).
Fifty serum samples from healthy, pregnant women
not receiving digitalis therapy were investigated with
4 methods. In addition, the samples were submitted
to Ultrafiltration, then measured by TDX; the results
are listed in table 2.
Table 3 shows the results from 20 umbilical cord blood
samples and 32 fetal blood samples without digoxin
therapy. Since there was no significant difference be-
tween these two sub-groups, the respective data were
combined.
Tab. l. Precision of four methods for the determination of digoxin.
Within assay
(N = 20)
Between assays
(N = 20)
Pl
P2
P3
P4
TDX
X
1.19
2.64
1.04
2.56
DELFIA
s
0.044
0.048
0.067
0.092
CV%
3.7
1.8
6.6
3.6
X
1.21
3.20
1.54
3.08
s
0.091
0.151
0.222
0.302
CV%
7.5
4.7
14.4
9.8
AMERLITE
X
1.14
2.94
1.14
2.87
s
0.051
0.091
0.068
0.132
CV%
4.5
3.1
6.0
4.6
RIA
X
1.01
2.62
0.96
2.84
s
0.064
0.055
0.084
0.145
CV%
6.3
2.1
8.7
5.1
Tab. 2. Concentration of digoxin-like immunoreactive factors (DLIF) in the serum of healthy pregnant women not receiving
digoxin.
Samples investigated
DLlF-positive samples
Medi n of DLIF in positive samples
(nmol/1)
TDX
50
50 (100%)
0.20
TDX
after
ultrafiltration
50
5 (10%)
0.02
DELFIA
50
21 (42%)
0.20
AMERLITE
50
9 (18%)
0.09
RIA
50
11 (22%)
0.09
Range of DLIF in positive samples
(nmol/1)
0.05-0.54 0.01-0.07 0.03-0.37 0.05-0.14 0.04-0.20
Tab. 3. Concentratipn of digoxin-like immunoreactive factors (DLIF) in fetal (N = 32) and in umbilical serum (N = 20) from
fetuses or newborn infants not receiving digoxin.
" '
Samples investigated
DLIF-positive samples
Medi n of DLIF in positive sara
TDX
52
52 (100%)
iples 0.63
TDX
after
ultrafiltration
52
14 (27%)
0.05
DELFIA
52
52 (100%)
0.61
AMERLITE
52
51 (98%)
0.18
RIA
52
4 (8%)
0.09
(nmol/1)
Range of DLIF in positive samples
(nmol/1)
0.31-0.92 0.01-0.09 0.33^-1.16 0.05-0.52 0.09-0.11
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Tab. 4. Concentration of digoxin-like immunoreactive factors (DLIF) in amniotic fluid (N = 33) from healthy women not
rcceiving digoxin.
TDX DELFIA AMERLITE RIA
Samples investigated
DLIF-positive samples
Mediän of DLIF in positive samples
(nmol/l)
Range of DLIF in positive samples
(nmol/l)
33
33 (100%)
0.32
0.09-0.96
33
33 (100%)
0.19
0.01-0.93
33
28 (85%),
0.14
0.01-0.55
33
0
0.5
"
W
1-0.5
a
5
2 3
Digoxin (RIA) [nmol/l]
^ 0.5
S
i °-°
l
c-0.5
lh
Digoxin (RIA) [nmol/l]
o
^
u? 0.5
erin
2
re
si
o Vn
Digoxin (RIA) [nmol/l]
Fig. l (a-c). Differences (y-axis) between the analytical values
obtained with TDX (a), DELFIA (b) or AMER-
LITE (c) and those obtained with RIA (x-axis)
in the serum of 57 digoxin-treated, non-pregnant
women.
Table 4 contains the results of the aüalysis of 33
amniotic fluid samples from pregnant women not
receiving digitalis therapy. Owiüg to the low protein
content, ultrafiltration of amniotic fluid does not lead
to a marked decrease of the concentration of "di-
goxin-like immunoreactive factors".
Figure l (a—c) shows the results of the method com-
parison on 57 serum samples from non-pregnant
women undergoiiig digoxin therapy. There is äs yet
no reference method for digoxin determination. How*
ever, since the RIA used here is not influenced by
"digoxin-like immunoreactive factors" (13, 21), or
only slightly (22) (see also tables 2—4), it was used
äs the reference for present purposes. Figure 2 shows
the effect of ultrafiltration.
w
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Fig. 2. Differences (y-axis) between the digoxin values meas-
ured with the TDX method after and before ultrafiltra-
tion (x-axis) in the serum of 35 digoxin-treated, non-
pregnant women.
Figure 3 (a—c) shows the results of the method com-
parison for 40 sera from pregnant women undergoing
digoxin therapy. Figure 4 shows the results of the
elimination of "digoxin-like immunoreactive factors"
by ültracentrifugation. > *
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Fig. 3 (a—c). Difierences (y-axis) between the analylical values
obtained with TDX (a), DELFIA (b) or AMER-
LITE (c) and those obtained with RIA (x-axis)
in the serum of 40 digoxin-treated pregnant
women.
Fig. 5 (a—c). Differences (y-axis) between the analytical values
obtained with TDX (a), DELFIA (b) or AMER-
LITE (c) and those obtained with RIA in the
serum of 20 digoxin-treated fetuses.
0.0
= -0.2
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Fig. 4. Differences (y-axis) between the digoxin values meas-
ured with the TDX method after and before ultrafiltra-
tion (x-axis) in the serum of 40 digoxin-treated pregnant
women.
0.5 1.0 15
Digoxin (TDX, before Ultrafiltration) [nmol/l]
Fig. 6. Differences (y-axis) between the digoxin values meas-
ured with the TDX method after and before ultrafiltra-
tion (x-axis) in the serum of 30 digoxin-treated fetuses.
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Tab. 5. Slatistical evaluation of the comparison of the three non-radioactive methods for digoxin determination with the
radioimmunoassay. (a = point of intersection of the axis, b = slope of the regression line; r = correlation coefficient;
d = difierence betwecn the average values from the investigated method and the radioimmunoassay).
Patient
Non pregnanl
womcn with
digoxin therapy
N = 57
Pregnant
women with
digoxin therapy
N = 40
Fetuses with
digoxin
therapy
N = 20
Method
TDX
DELFIA
AMERLITE
TDX
DELFIA
AMERLITE
TDX
DELFIA
AMERLITE
TDX
after Ultrafiltration
a
0.208*
0.323*
0.026
0.022
0.417*
0.080
0.249*
0.375*
0.006
-0.055
b
0.923
1.028
1.105**
1.047
0.942
0.970
0.981
1.000
1.027
1.058
r*
0.930
0.913 ,
 f
0.943
0.967
0.949
0.979
0.952
0.923
0.983
0.988
d
-0.09
0.31***
0.21***
0.05***
0.29***
-0.05
0.26***
0.32***
0.03
0.00
* The hypothesis a = 0 is rejected (p < 0.05)
** The hypothesis b = l is rejected (p < 0.05)
*** The hypothesis d = 0 is rejected (p < 0.05)
For all values of r : p < 0.01
Tab. 6. Statistical evaluation of the analytical results with the TDX method before and after Ultrafiltration (a = point of intersection
of the axis, b = slope of the regression line, r = correlation coefficient; d = difference between the average analytical
values after and before ultrafiltration).
Patient
Non pregnant women with digoxin therapy
N = 35
Pregnant women with digoxin therapy
N = 26
Fetuses with digoxin therapy
N = 30
a
-0.083
-0.075
-0.293*
b
1.031
0.972
1.037
r*
0.988
0.965
0.961
d
0.00
-0.18***
-0.26***
* The hypothesis a = 0 is rejected (p < 0.05)
*** The hypothesis d = 0 is rejected (p < 0.05)
For all values of r : p < 0.01
Figure 5 (a—c) and figure 6 show the results of
measurements in blood from fetuses receiving digoxin
medication.
Statistics for the comparison of each method with the
radioimmunoassay (used here äs the "reference
method") (figs l, 3 and 5) are given in table 5. The
corresponding data for the comparison before and
after ultrafiltration are given in table 6.
Discussion
Endogenous, digoxin-like immunoreactive factors
(DLIF) are substances in plasma (or serum), which
react with antibodies against digoxin. These factors
are found in patients with liver and kidney diseases,
but they are especially prevalent in pregnant women
and newborn infants. Their identification and quan-
titative determination would be of considerable phys-
iological and methodological interest, äs well äs en-
abling an improvement of the accuracy of immuno-
logical digoxin determination (10 — 12).
In patients receiving digoxin therapy, cardio-inactive
metabolites of digoxin can react in the immunoassay,
resulting in erroneously high apparent digoxin con-
centrations (23-25). The "digoxin-like immunoreac-
tive factors" in patients not receiving digoxin therapy
have so far been characterized only superficially; the
findings are often speculative and contradictory (26,,
27).
"Digoxin-like immunoreactive factors" can «be sub-
divided into two groups: factors which only react with
antibodies against digoxin, and those which also in-
hitiit the Na,K-ATPase, thereby possibly playing a
role in the regulation of blood »pressure (for review
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see 1. c. (28)). Fatty acids (27, 29), phospholipids (27,
30), steroids (31), and bile acids (32, 33) have all been
suggested äs "digoxin-like immunoreactive factors",
with varying degrees of probability. "Digoxin-like im-
munoreactive factors" certainly represent a hetero-
geneous group of substances, with certain common
properties and characteristics, i.e. water solubility,
heat stability, resistance to proteolytic enzymes and a
relative molecular mass Mr < 1000 (34).
Difficulties and contradictions in the investigation of
"digoxin-like immunoreactive factors" are due in no
small part to the methodological problems that they
cause in the quantitative determination of digoxin,
and the fact that the magnitude of their interference
in the digoxin assay depends on the radioimmunoas-
say used (35). Even high-performance liquid chro-
matography (HPLC) or a combination of HPLC with
an immunoassay has so far not resulted in a reference
method (23, 24, 36, 37).
In the present work, four immunochemical methods
for the determination of digoxin are compared, which
differ principally in their detection Systems. A "clas-
sical" competitive radioimmunoassay was investi-
gated, together with a fluorescence polarization im-
munoassay (Abbott TDX), a time-resolved fluoroim-
munoassay (DELFIA) and a luminescence-amplified
enzyme-immunoassay (AMERLITE).
RIA, TDX and AMERLITE show similar values for
precision in series. Day to day precision is also very
similar for the three methods, the RIA showing only
a slightly greater scattef than the TDX and AMER-
LITE methods (tab. 1). The largest Variation coeffi-
cients, both in series and from day to day, were found
for the DELFIA method. So far, the only published
detailed studies of the DELFIA digoxin assay are
those of the manufacturer (38), who reported Varia-
tion coefficients much lower than those found in the
present work.
For the comparison of methods, an established RIA
was used äs the reference method. Accordijig to the
literature (13, 21, 22), this method employs highly
specific anti-digoxin antibodies, and it is only slightly
influenced by "digoxin-like immunoreactive factors".
In the analysis of 57 sera from non-pregnant women
receiving digoxin, the results from the TDX showed
the closest correspondence (i.e. the smallest differ-
ences) with those from the RIA (fig. l a, tab. 5); the
difference of 0.09 nmol/1 between the average values
from the two assays is not significantly different from
zero. On the other band, the results from AMERLITE
and DELFIA differed significantly (0.21 nmol/1 and
0.31 nmol/1, respectively) from the RIA results.
Various reasons for these differences can be deduced
from the statistical data for the regression functions
(tab. 'S): the differences between the RIA and AMER-
LITE results can be essentially explained by different
standardization procedures (b 1), whereas DEL-
FIA shows systematic differences over the entire an-
alytical ränge (a 7* 0). It is noticeable that the TDX
values are higher than the RIA values in the lower
analytical ränge, and lower in the upper analytical
ränge.
The binding of both "digoxin-like immunoreactive
factors" and digoxin to protein is markedly temper-
ature-dependent (34, 39). At 37 °C, 20-25% of di-
goxin is bound to plasma proteins, but only about
5% is bound at 4 °C. Most of the "digoxin-like im-
munoreactive factors" appear to be bound to plasma
proteins, and the binding decreases at higher temper-
atures. Ultrafiltration of serum at 2—4°C should
therefore remove most (16) or all (17) of the "digoxin-
like immunoreactive factors" without loss of digoxin.
Since this procedure has so far been tried on only a
few samples, 35 serum samples from non-pregnant
patients under digoxin therapy were analysed with
TDX before and after Ultrafiltration.
Figure 2 and table 6 show that under these conditions
the recovery of digoxin is 100%.
In the analysis of 50 samples from healthy pregnant
women not receiving digoxin, the results showed a
marked dependency on the method (tab. 2). "Digoxin-
like immunoreactive factors" were detected in all sam-
ples with TDX, in 42% of samples with DELFIA, and
in only 18% of samples with AMERLITE. However,
the RIA was also influenced by "digoxin-like immu-
noreactive factors" with surprisingly high frequency
(22%).
From the individual values of the above analyses it
is clear that the results are influenced by the different
specificities of the various antibodies. Depending on
the analytical method, the highest values for "digoxin-
like immunoreactive factors" were found in different
sera. Thus, the sample containing the highest value
when analysed with TDX (0.54 nmol/1), gave a value
of 0.13 nmol/1 with AMERLITE and < 0.01 nmol/1
with RIA and DELFIA. The highest concentration
recorded with RIA (0.20 nmol/1) was recorded äs 0.32
nmol/1 with TDX, 0.35 nmol/1 with DELFIA and 0.07
nmol/1 with AMERLITE.
The TDX- and DELFIA-values show no correlation
(r = 0.011), while a weak correlation exists between
the TDX- and AMERLITE-values (r = 0.316). From
this it can be concluded that, at least in the case of
TDX and DELFIA, the substances acting äs "digoxin-
like immunoreactive factors" are different.
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Ullrafiltration is very effective for the elimination of
"digoxin-like immunoreactive factors". Christenson
(17) found no "digoxin-like immunoreactive factors"
in 17 ultrafiltered pregnancy sera, whereas our own
studies showed a 90% decrease of "digoxin-like im-
munoreactive factors", in agreement with the results
of Graves et al. (16).
Much higher concentrations of "digoxin-like immu-
noreactive factors" are found in the umbilical cord
blood and in the blood of untreated fetuses (tab. 3).
Here also, the results are markedly method-depend-
ent: "Digoxin-like immunoreactive factors" were
found in only 8% of samples with RIA, whereas the
non-radioactive methods detected "digoxin-like im-
munoreactive factors" in 100% (or 98%) of the sam-
ples. The highest concentrations were found with TDX
and DELFIA, but here again comparison of the in-
dividual values reveals only a weak correlation
(r = 0.133) between the two methods. The high spec-
ificity of the RIA is especially evident from the anal-
yses of umbilical and fetal blood samples. We cannot,
however, confirm the Statement by the AMERLITE
manufacturer that the influence of "digoxin-like im-
munoreactive factors" on this assay is "relatively
small or non-existent".
Ultrafiltration also efficiently removes "digoxin-like
immunoreactive factors" from fetal and umbilical
blood, the concentrations being reduced on average
by 92%.
Amniotic fluid, which consists largely of fetal urine,
contains (depending of the analytical method) rela-
tively high concentrations of "digoxin-like immuno-
reactive factors" (tab. 4). Ultrafiltration is not effec-
tive in the removal of "digoxin-like immunoreactive
factors" from amniotic fluid, because the latter con-
tains only a low concentration of protein.
No systematic studies have so far been published on
the determination of digoxin in sera from pregnant
women treated with digitalis preparations, or in the
sera of digoxin-treated fetuses.
We investigated 40 sera from pregnant women treated
with digitalis for fetal tachyarrhythmia. The results
are shown in figure 3 (a—c) and table 5. In addition,
the samples were ultrafiltered and analysed by
the fluorescence-polarization-immunoassay (fig. 4,
tab. 6).
Based on the assumption that also under digitalis
therapy, 90% of the "digoxin-like immunoreactive
factors" in pregnancy serum can be eliminated by
Ultrafiltration, the average "digoxin-like immunoreac-
tive factors" concentration of 0.18 nmol/1 removed
by Ultrafiltration (tab. 6) corresponds exactly to the
average concentration of 0.2 nmol/1 in the serum of
non-treated pregnant women (tab. 2). The maximal
concentrations are also practically identical (fig. 4,
tab. 2).
However, a different relationship is found between
the results of the RIA and the thtfee non-radioactive
methods.
Thus, compared with the systematic differences be-
tween RIA and TDX, or between RIA and DELFIA
for the analysis of non-pregnaiicy serum (fig. l (a—b),
tab. 5) even greater differences would be anticipated
for the analysis of pregnancy serum, because TDX
and DELFIA are more influenced by "digoxin-like
immunoreactive factors" than is the RIA (tab. 2).
This is not apparent from the gräphical presentation
of the individual data (fig. 3 (a—b)), or from the
statistical evaluation. The average differences between
RIA and TDX, or between RJA and DELFIA become
smailer (TDX: 0.09/0.06 nmol/1; DELFIA: 0.31/0.29
nmol/l)5 rather than increasing by 0.11 nmol/1 äs ex-
pected.
We conclude from this that the composition of the
"digoxin-like immunoreactive factors" changes in
pregnancy under digoxin therapy, and that the RIA
is particularly affected by this changed "digoxin-like
immunoreactive factors". This theory is supported by
comparison of the results from RIA and AMERLITE
(fig. 3c). In non-pregnant women, the AMERLITE
values were on average 0.21 nmol/1 higher than the
RIA values, whereas they were 0.05 nmol/1 lower in
sera from pregnant women treated with digitalis, de-
spite the fact that both methods are influenced in
identical fashion by the "digoxin-like immunoreactive
factors" in non^pregnancy sera.
The results from the analysis of sera from digoxin-
treated fetuses were especially surprising.
In 30 samples measured with TDX before and after
ultrafiltration, the average eliminated digoxin concen-
tration was 0.26 nmol/1 (ränge: 0.07-0.44 nmol/1)
(fig. 6, tab. 6). Assuming that 90% of "digoxin-like
immunoreactive factors" are eliminated by ultrafiltra-
tion, comparison with the results in table 3 indicates
that the average concentration of "digoxin-like im-
munoreactive factors" in the blood of treated fetuses
is only 46% of that in untreated fetuses.
The RIA and AMERLITE values are not significantly
different from the TDX values after ultrafiltration
(tab. 5). Before ultrafiltration, however, the values
obtained with TDX and with DELFIA are markedly
higher than the RIA values (fig. 5). Thus, under
digoxin therapy, fetal blood also contains an altered
population of "digoxin-like immunoreactive factors",
which affect the various assays in different ways.
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The observed decrease of the concentration of "di-
goxin-like immunoreactive factors" in fetuses under
digoxin therapy appears to contradict the results of
Weiner et al. (40), which are just the opposite of ours.
These authors, however, could not differentiate ana-
lytically between digoxin and "digoxin-like immuno-
reactive factors", so that their high "DLIF" concen-
tration in the serum of treated fetuses may well be
explained by the transfer of digoxin across the pla-
centa.
In a recently published study (41), Paci et al. reported
the presence of specific receptors for digoxin on the
placental membrane; "digoxin-like immunoreactive
factors" are especially tightly bound by these recep-
tors, thereby inhibiting the binding of digoxin.
The majority of the treated pregnant women in our
collective, ultrasonography showed a hydropic pla-
centa, which was up to twice the size of a normal
placenta. It seems possible that the number of recep-
tors is increased in hydropic placentas, which would
explain the decrease in the concentration of "digoxin-
like immunoreactive factors".
Conclusions
1. The varying sensitivity to "digoxin-like immuno-
reactive factors" already described for various ra-
dioimmunoassays is also displayed by the non-radio-
active methods investigated in the present wprk. The
greatest sensitivity to "digoxin-like immunoreactive
factors" in pregnancy serum is shown by the TDX
method, followed by DELFIA, RIA, AMERLITE
and finally by TDX for the analysis of the ültrafilträte.
For fetal and umbilical blood, the order is TDX —»
DELFIA -> AMERLITE -> RIA -+ TDX (ultrafil-
trate). Concentrations of "digoxin-like immunoreac-
tive factors" vary greatly over a wide ränge, and it is
therefore not possible to correct analytical results by
subtracting a constant value for this unspecific inter-
ferenee.
2. Digoxin therapy during pregnancy alters the spec-
trum of "digoxin-like immunoreactive factors", which
affects the sensitivity of the assay (especially the RIA)
to "digoxin-like immunoreactive factors". The lowest
values for "digoxin-like immunoreactive factors" are
found in ultrafiltered samples, using the TDX method.
This latter method, and not the RIA, can therefore
be recommended äs the method with the highest spec-
ificity.
3. Under digoxin therapy, the concentration of "di-
goxin-like immunoreactive factors" in fetal blood is
decreased to about half of that in untreated fetuses.
The most plausible results are obtained by analysis
of the ultrafiltered serum from fetuses undergoing
digoxin therapy with the TDX method; however, RIA
and AMERLITE give practically identical results.
4. Owing to its poor precision and high sensitivity to
"digoxin-like immunoreactive factors", the DELFIA
method is the least suitable for the monitoring of
digoxin therapy in maternal and fetal blood.
5. Measurement of digoxin with the fluorescence-
polarization-immunoassay after ultrafiltration of the
serum sample yields the most accurate results. With
this method, the requirement for a quick analysis of
a single sample can also be met.
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